SecBot SecBot
PRESS-RELEASE ·Filed Jun 29, 2026

DNTH

Dianthus Therapeutics, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor Phase 2 MoMeNtum data in MMN (Q4'26) and CAPTIVATE Part B update (YE'26) as nearer-term catalysts; Phase 3 gMG data (2H'28) is too distant to drive near-term price action. Insider selling ahead of this announcement may signal limited upside in the near term.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$95.68
T+0 close · Jun 29, 2026 · via day close
Latest settled
+2.79%
T+60 · $98.35
Vs SPY
−1.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $95.68entry
  2. T+1 · 5mo ago +1.88%α +1.10% · $97.48
  3. T+5 · 4mo ago −2.45%α −3.83% · $93.34
  4. T+20 · 4mo ago +8.56%α +8.84% · $103.87
  5. T+60 · 8w ago +2.79%α −1.60% · $98.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis, building on positive Phase 2 results. Top-line data expected in 2H'28; the stock may see modest positive momentum from trial advancement but major catalysts are distant.

Key Facts

  • Phase 3 EMERGE trial initiated in ~195 AChR+ gMG patients with claseprubart 300mg Q2W or Q4W
  • Primary endpoint: change from baseline in MG-ADL; top-line results expected 2H'28
  • Claseprubart granted Orphan Drug Designation by FDA for MG in May 2026
  • Phase 2 MaGic trial showed rapid, sustained, statistically significant improvements vs placebo
  • Additional catalysts: MMN Phase 2 data Q4'26, CIDP Phase 3 Part B timing update by YE'26

Financial Impact

No direct revenue impact; pipeline progression supports valuation but revenues years away

pipeline value

Risk Factors

  • Clinical trial failure or disappointing efficacy/safety
  • Competition from existing and emerging gMG therapies
  • Dilution risk if additional capital is needed before data readouts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3318826

Track record

23 reports on DNTH

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026